Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Theralase AUA Poster

<< Previous

Bullboard Posts

Next >>

Comment by DJDawgon May 01, 2023 12:06pm

174 Views

Post# 35422962

RE:RE:RE:Theralase AUA Poster

Fred. Regardless of the data representation we can all agree:

a) 90 day CR is 53.8% even if you include the under-treated. So likely higher.
b) 90 day TR is 65.4% even if you include the under-treated. So likely higher.
c) the proportion of the CR that stay CR till 450 is very good.
d) there are a total of 13 other patients who were CR from day 90 and are still CR making for better and better data.

Regardless of how the tables display? Can we all agree and stop going back and forth on this one.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market